Teczem (enalapril maleate/diltiazem malate)

The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.

Approval Status:

Approved October 1996

Specific Treatments:


Find Related Trials for The Following Conditions

General Information

Teczem has been approved for the treatment of hypertension. Teczem combines two compounds in a single tablet. Vasotec, manufactured by Merck, is the brand name for enalapril. Cardizem, manufactured by Hoechst Marion Roussel, is the brand name for diltiazem. Indicated for the initial treatment of high blood pressure, Teczem will be manufactured by Merck and marketed by Hoechst Marion Roussel.

Mechanism of Action

Teczem is the first combination product of an ACE inhibitor and a non-dihydropyridine calcium channel blocker. Non-dihydropyridine calcium channel blockers are distinguished by their heart-rate lowering action in the treatment of hypertension.